Renalytix Shares Surge 19% Following £10.5 Million Fundraise

Key Facts

1Renalytix shares jumped 19% to 5p as trading resumed on the AIM market.

2The company successfully raised £10.5 million through a fundraising effort involving institutional and retail investors.

In a move reflecting renewed investor confidence following a critical liquidity injection, Renalytix shares jumped 19% to 5p as trading resumed on the AIM market. This surge follows a temporary trading suspension initiated in early September to facilitate a new investment round. According to reports, the company successfully raised £10.5 million through a fundraising effort involving both institutional and retail investors, providing a vital lifeline for the firm's operations.

The company plans to utilize the proceeds to fund the US rollout of its kidney diagnostic test through a national healthcare network, targeting 25,000 tests by 2027. The fundraising included approximately £10.1 million secured from major investors and £380,000 from a retail offer. Under a deal signed on September 1, doctors will be able to order tests directly through existing systems, significantly expanding the company's commercial reach in the American market.

Looking ahead, the company still requires shareholder approval at a meeting later this month for a remaining £3.9 million portion of the funding. If approved, a further batch of new shares is expected to commence trading on September 29, 2026. As authoritative price data is unavailable as of the close on September 8, 2026, the stock's bullish momentum remains contingent on the successful execution of these expansion plans and upcoming corporate approvals.